[A16-31] Eribulin (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V
Last updated 01.12.2016
Project no.:
A16-31
Commission:
Commission awarded on 01.06.2016 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A16-65 | Eribulin (liposarcoma) - Addendum to Commission A16-31 | Commission completed |
| A14-25 | Eribulin (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
| A11-26 | Eribulin - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
Federal Joint Committee (G-BA)
2016-12-01 A G-BA decision was published.